Over 750 volunteers have been administered the first dose of Bharat Biotech's COVID-19 vaccine 'Covaxin' as part of its phase-3 trials at a city hospital, and none of them have experienced any side effects so far, a senior doctor said on Sunday. Bharat Biotech is developing Covaxin in collaboration with the Indian Council of Medical Research (ICMR)-National Institute of Virology (NIV).

Over 750 volunteers have been administered the first dose of Bharat Biotech's COVID-19 vaccine 'Covaxin' as part of its phase-3 trials at a city hospital, and none of them have experienced any side effects so far, a senior doctor said on Sunday. Bharat Biotech is developing Covaxin in collaboration with the Indian Council of Medical Research (ICMR)-National Institute of Virology (NIV).